Yanchuang Capital
Overview
Yanchuang Capital was founded in 2010 by the Office of Science and Technology of Peking University and PKU alumni. It focuses on equity investments, stock market securities investments, and M&A. In the healthcare sector, Yanchuang has invested in a number of biopharma / biotech companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Volant Aerotech | Dec 2024 | VC Round | Co-investor |
| Apollomics | Nov 2020 | Series C | Co-investor |
| Laekna, Inc. | May 2022 | Series D | Co-investor |
| EpimAb Biotherapeutics | Mar 2021 | Series C | Co-investor |
| RaySea Technology | Sep 2020 | Series A Extension | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Yanchuang Capital based?
Yanchuang Capital is headquartered in Beijing.
When was Yanchuang Capital founded?
Yanchuang Capital was founded in 2010.
How many portfolio companies does Yanchuang Capital have?
Yanchuang Capital has 9 portfolio companies in Caplight's dataset.
What are some companies in Yanchuang Capital's portfolio?
Portfolio companies visible on Caplight include Volant Aerotech, Apollomics, Laekna, Inc., EpimAb Biotherapeutics, RaySea Technology.
What was Yanchuang Capital's most recent investment shown here?
Yanchuang Capital's most recent investment in this portfolio sample was in Volant Aerotech in 2024.
What sectors does Yanchuang Capital focus on?
Yanchuang Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, FinTech, Frontier & Industrial Tech, Mobility, Transportation & Logistics, Frontier & Industrial Tech, Telecommunications & Networking, Enterprise Software.
What company stages does Yanchuang Capital focus on?
Yanchuang Capital typically invests at the MultiStage stage.
What is Yanchuang Capital's AUM?
Yanchuang Capital's assets under management are estimated between $500.0M and $1.0B.